The world’s largest diabetes drug-maker, Novo Nordisk (NYSE:NVO), is reportedly looking to boost its efforts to treat obesity as the company’s well-established diabetes drugs face competition. At Novo Nordisk’s capital markets day yesterday, CEO Lars Fruergaard Jorgensen told investors that the company wants to rival surgery with their drugs as a solution for obesity. The drug-maker’s first […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Dexcom, Lilly ink deal to combine CGM into smart insulin delivery device
Dexcom (NSDQ:DXCM) said today that it inked a development deal with Eli Lilly (NYSE:LLY) to include its continuous glucose monitor in the insulin-maker’s connected delivery devices. The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with diabetes. […]
JDRF touts win after Anthem decides to cover artificial pancreas systems
JDRF said today it successfully persuaded Anthem to cover artificial pancreas systems, after meeting the health insurer as part of its Coverage2Control campaign. America’s 25 largest health insurers now cover Medtronic‘s (NYSE:MDT) MiniMed system, according to the organization. Get the full story at our sister site, Drug Delivery Business News.
Researchers reverse diabetes in mice by infusing them with blood stem cells
Researchers at Boston Children’s Hospital successfully reversed Type I diabetes in a mouse model using blood stem cells, according to a study published this week in Science Translational Medicine. The researchers used cells that were pre-treated to make more of a protein, PD-L1, which is deficient in mice and people with Type I diabetes. “There’s really a reshaping […]
Insulia wins FDA nod, CE Mark clearance to titrate Tresiba, Basaglar insulin
Voluntis said today that its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate basal insulin brands Tresiba and Basaglar. The company’s software already works with Lantus, Toujeo and Levemir. The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. […]
Bigfoot Biomedical CEO hits back against CMS over data-sharing decision
Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has said that […]
How DarioHealth turned the smartphone into a user-friendly glucose monitor
When DarioHealth (NSDQ:DRIO) CEO Erez Raphael looks at the medical device world, he sees solutions that were designed by healthcare professionals and doctors – and this presents a stark contrast with the consumer device industry, he pointed out. “We have seen there are a lot of cases, most of the cases in the industry, where the […]
GI Dynamics loses CE Mark certificate for EndoBarrier
GI Dynamics (ASX:GID) said yesterday that its notified body in Europe withdrew its certification for CE Mark approval for its EndoBarrier device, meaning the company can no longer sell the obesity and diabetes treatment in the European Union. CEO Scott Schorer told MassDevice.com today during a telephone interview that Boston-based GID passed an intensive, week-long inspection of […]
Study: Glytec’s diabetes management tech improves care for patients leaving the hospital
A prospective study conducted by Eastern Virginia Medical School showed that patients had no diabetes-related readmissions or ER visits within 30 days of leaving the hospital when providers used the Hospital-to-Home module of Glytec‘s eGlycemic diabetes management system. Twenty-eight people with diabetes were enrolled in the study and all of them had A1C levels above 6.5% […]
Innovus inks deal to sell Acon’s glucose monitoring kit
Innovus Pharmaceuticals (OTC:INNV) announced today that it has inked an agreement with its current partner, Acon Laboratories, to sell Acon’s FDA-cleared glucose monitor, test strips and lancet device. The San Diego, Calif.-based company plans to sell Acon’s glucose testing kit with its GlucoGorx glucose supplement. Get the full story at our sister site, Drug Delivery Business News.
Insulet up-sizes and prices $350m private placement
Insulet (NSDQ:PODD) up-sized the private placement that it announced yesterday, citing strong investor demand. The Billerica, Mass.-based company said today it plans to offer $350 million in convertible senior notes due in 2024, up from $300 million. Get the full story at our sister site, Drug Delivery Business News.